Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803480 | 0.84 | NPC1 (0.51) | LMNAPDK2NPC1PDCD1CD274 | |
| SCHEMBL16673182 | 0.84 | MRGPRX1 (0.49) | LMNAGAAPDK2NPC1MRGPRX1 | |
| SCHEMBL28534333 | 0.83 | PDK2 (0.46) | LMNAGAAPDK2NPC1PDCD1 | |
| SCHEMBL137907 | 0.81 | NPC1 (0.62) | LMNAPDK2NPC1PDCD1CD274 | |
| SCHEMBL16672680 | 0.81 | LMNA (0.42) | LMNAGAAPDK2NPC1MRGPRX1 | |
| SCHEMBL45490 | 0.80 | LMNA (0.59) | LMNAGAAPDK2CA1CA2 | |
| SCHEMBL20332068 | 0.80 | MAPT (0.49) | PDK2CA12CA1CA2CA7 | |
| SCHEMBL10519876 | 0.80 | LMNA (0.58) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL1405144 | 0.80 | LMNA (0.58) | LMNAGAAMRGPRX1KCNK3KCNK9 | |
| SCHEMBL7031981 | 0.79 | NPC1 (0.45) | LMNAGAAPDK2NPC1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | LMNA 2534/4885GAA 1053/4885PDK2 4806/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | LMNA 3752/4885GAA 3778/4885PDK2 4368/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | LMNA 2534/4885GAA 1053/4885PDK2 4806/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | LMNA 2534/4885GAA 1053/4885PDK2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.